Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019

Xencor management will host a webcast and conference call the same day at 4:30 p.m.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Tuesday, October 29, 2019
Information
Tags: 
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Medical specialties, Medicine, Life sciences, Immunology, Immune system, Biotechnology, Monoclonal antibody, Biopharmaceutical, Antibody, Allergy
Geotags: 
California, United States
⚠ generated by AI ↴
Organisation: 
XENCOR, INC.
Summary
Key Points: 
  • Xencor management will host a webcast and conference call the same day at 4:30 p.m.
  • ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
  • A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases.


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release third quarter 2019 financial results after the market closes on Tuesday, November 5, 2019.

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 9415077. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. The webcast will be archived on the company website for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Copyright: 
Copyright Business Wire 2019